Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETCF | ISIN: CNE100006624 | Ticker-Symbol: R9Z
Frankfurt
04.04.25
15:29 Uhr
0,730 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC Chart 1 Jahr
5-Tage-Chart
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7300,85016:31

Aktuelle News zur IMMUNEONCO BIOPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-003/IMM72-
26.03.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD-
26.03.ImmuneOnco axes CD47 bispecific as pipeline prioritization pressures hit Chinese biotech1
IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln
25.03.IMMUNEONCO-B (01541): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED CHANGE IN USE OF PROCEEDS-
14.03.IMMUNEONCO-B (01541): INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY-
13.03.IMMUNEONCO-B (01541): DATE OF BOARD MEETING-
05.03.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) COMBINED WITH IMM2510 (PALVERAFUSP) AND ...1
21.02.IMMUNEONCO-B (01541): COMPLETION OF DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY1
17.02.IMMUNEONCO-B (01541): (REVISED) SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY1
24.01.IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION1
24.01.IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION1
13.01.IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH CHEMOTHERAPY FOR THE ...-
10.01.IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY2
09.01.IMMUNEONCO-B (01541): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG1
30.12.24IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY1
17.12.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF NMOSD1
28.11.24IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN-
28.11.24IMMUNEONCO-B (01541): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE3
20.11.24IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE1
18.11.24IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM03061
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1